The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.La présente invention concerne des procédés pour traiter des maladies ou des affections dans lesquelles lexpression ou lactivité de proprotéine convertase subtilisine/kexine type 9 (PCSK9) a un impact par administration danticorps spécifiques pour PCSK9 ou de fragments de liaison dantigène de ceux-ci et de préférence par administration additionnelle dun inhibiteur de 3-hydroxy-3-méthyl-glutaryl-CoA réductase (HMG-CoA réductase). La présente invention concerne en outre des anticorps spécifiques pour PCSK9 ou des fragments de liaison dantigène de ceux-ci pour utilisation dans le traitement de maladies ou affections dans lesquelles lexpression ou lactivité de PCSK9 a un impact. La présente invention concerne en outre des articles de fabrication com
